CANCER:

Cholangiocarcinoma

Related cancers:

‹

Biliary Tract Cancer (244)

Gallbladder Cancer (36)

Biliary Tract Cancer (244)

Gallbladder Cancer (36)

›

FGFR2 rearrangement FGFR2 rearrangement	Cholangiocarcinoma Cholangiocarcinoma	FGFR2 rearrangement FGFR2 rearrangement	Cholangiocarcinoma Cholangiocarcinoma	TAS 120 Sensitive: B - Late Trials ASCO-GI 2022 - 1 week	TAS 120 Sensitive: B - Late Trials ASCO-GI 2022 - 1 week
FGFR2 fusion FGFR2 fusion	Cholangiocarcinoma Cholangiocarcinoma	FGFR2 fusion FGFR2 fusion	Cholangiocarcinoma Cholangiocarcinoma	TAS 120 Sensitive: B - Late Trials ASCO-GI 2022 - 1 week	TAS 120 Sensitive: B - Late Trials ASCO-GI 2022 - 1 week
FGFR3 mutation FGFR3 mutation	Cholangiocarcinoma Cholangiocarcinoma	FGFR3 mutation FGFR3 mutation	Cholangiocarcinoma Cholangiocarcinoma	erdafitinib Sensitive: C1 - Off-label ASCO-GI 2022 - 1 week	erdafitinib Sensitive: C1 - Off-label ASCO-GI 2022 - 1 week
FGFR2 mutation FGFR2 mutation	Cholangiocarcinoma Cholangiocarcinoma	FGFR2 mutation FGFR2 mutation	Cholangiocarcinoma Cholangiocarcinoma	erdafitinib Sensitive: C1 - Off-label ASCO-GI 2022 - 1 week	erdafitinib Sensitive: C1 - Off-label ASCO-GI 2022 - 1 week
FGFR2 mutation FGFR2 mutation	Cholangiocarcinoma Cholangiocarcinoma	FGFR2 mutation FGFR2 mutation	Cholangiocarcinoma Cholangiocarcinoma	ARQ 087 Sensitive: C2 – Inclusion Criteria ASCO-GI 2022 - 1 week	ARQ 087 Sensitive: C2 – Inclusion Criteria ASCO-GI 2022 - 1 week
FGFR2 amplification FGFR2 amplification	Cholangiocarcinoma Cholangiocarcinoma	FGFR2 amplification FGFR2 amplification	Cholangiocarcinoma Cholangiocarcinoma	ARQ 087 Sensitive: C2 – Inclusion Criteria ASCO-GI 2022 - 1 week	ARQ 087 Sensitive: C2 – Inclusion Criteria ASCO-GI 2022 - 1 week
FGFR1 fusion FGFR1 fusion	Cholangiocarcinoma Cholangiocarcinoma	FGFR1 fusion FGFR1 fusion	Cholangiocarcinoma Cholangiocarcinoma	erdafitinib Sensitive: C3 – Early Trials ASCO-GI 2022 - 1 week	erdafitinib Sensitive: C3 – Early Trials ASCO-GI 2022 - 1 week
FGFR2 mutation FGFR2 mutation	Cholangiocarcinoma Cholangiocarcinoma	FGFR2 mutation FGFR2 mutation	Cholangiocarcinoma Cholangiocarcinoma	KIN-3248 Sensitive: D – Preclinical ASCO-GI 2022 - 1 week	KIN-3248 Sensitive: D – Preclinical ASCO-GI 2022 - 1 week
FGFR2 rearrangement FGFR2 rearrangement	Cholangiocarcinoma Cholangiocarcinoma	FGFR2 rearrangement FGFR2 rearrangement	Cholangiocarcinoma Cholangiocarcinoma	infigratinib Sensitive: A1 - Approval	infigratinib Sensitive: A1 - Approval
FGFR2 fusion FGFR2 fusion	Cholangiocarcinoma Cholangiocarcinoma	FGFR2 fusion FGFR2 fusion	Cholangiocarcinoma Cholangiocarcinoma	infigratinib Sensitive: A1 - Approval	infigratinib Sensitive: A1 - Approval
IDH1 mutation IDH1 mutation	Cholangiocarcinoma Cholangiocarcinoma	IDH1 mutation IDH1 mutation	Cholangiocarcinoma Cholangiocarcinoma	ivosidenib Sensitive: A1 - Approval	ivosidenib Sensitive: A1 - Approval
FGFR2 rearrangement FGFR2 rearrangement	Cholangiocarcinoma Cholangiocarcinoma	FGFR2 rearrangement FGFR2 rearrangement	Cholangiocarcinoma Cholangiocarcinoma	pemigatinib Sensitive: A1 - Approval	pemigatinib Sensitive: A1 - Approval
FGFR2 fusion FGFR2 fusion	Cholangiocarcinoma Cholangiocarcinoma	FGFR2 fusion FGFR2 fusion	Cholangiocarcinoma Cholangiocarcinoma	pemigatinib Sensitive: A1 - Approval	pemigatinib Sensitive: A1 - Approval
No biomarker No biomarker	Cholangiocarcinoma Cholangiocarcinoma	No biomarker No biomarker	Cholangiocarcinoma Cholangiocarcinoma	gemcitabine + albumin-bound paclitaxel Sensitive: A2 - Guideline	gemcitabine + albumin-bound paclitaxel Sensitive: A2 - Guideline
No biomarker No biomarker	Cholangiocarcinoma Cholangiocarcinoma	No biomarker No biomarker	Cholangiocarcinoma Cholangiocarcinoma	gemcitabine Sensitive: A2 - Guideline	gemcitabine Sensitive: A2 - Guideline
No biomarker No biomarker	Cholangiocarcinoma Cholangiocarcinoma	No biomarker No biomarker	Cholangiocarcinoma Cholangiocarcinoma	infigratinib Sensitive: B - Late Trials	infigratinib Sensitive: B - Late Trials
HER-2 expression HER-2 expression	Cholangiocarcinoma Cholangiocarcinoma	HER-2 expression HER-2 expression	Cholangiocarcinoma Cholangiocarcinoma	trastuzumab + lapatinib Sensitive: B - Late Trials	trastuzumab + lapatinib Sensitive: B - Late Trials
No biomarker No biomarker	Cholangiocarcinoma Cholangiocarcinoma	No biomarker No biomarker	Cholangiocarcinoma Cholangiocarcinoma	TT-00420 Sensitive: B - Late Trials	TT-00420 Sensitive: B - Late Trials
RET fusion RET fusion	Cholangiocarcinoma Cholangiocarcinoma	RET fusion RET fusion	Cholangiocarcinoma Cholangiocarcinoma	pralsetinib Sensitive: C1 - Off-label	pralsetinib Sensitive: C1 - Off-label
BRCA2 mutation BRCA2 mutation	Cholangiocarcinoma Cholangiocarcinoma	BRCA2 mutation BRCA2 mutation	Cholangiocarcinoma Cholangiocarcinoma	olaparib Sensitive: C1 - Off-label	olaparib Sensitive: C1 - Off-label
BRCA1 mutation BRCA1 mutation	Cholangiocarcinoma Cholangiocarcinoma	BRCA1 mutation BRCA1 mutation	Cholangiocarcinoma Cholangiocarcinoma	olaparib Sensitive: C1 - Off-label	olaparib Sensitive: C1 - Off-label
NTRK3 fusion NTRK3 fusion	Cholangiocarcinoma Cholangiocarcinoma	NTRK3 fusion NTRK3 fusion	Cholangiocarcinoma Cholangiocarcinoma	larotrectinib Sensitive: C1 - Off-label	larotrectinib Sensitive: C1 - Off-label
NTRK2 fusion NTRK2 fusion	Cholangiocarcinoma Cholangiocarcinoma	NTRK2 fusion NTRK2 fusion	Cholangiocarcinoma Cholangiocarcinoma	larotrectinib Sensitive: C1 - Off-label	larotrectinib Sensitive: C1 - Off-label
NTRK1 fusion NTRK1 fusion	Cholangiocarcinoma Cholangiocarcinoma	NTRK1 fusion NTRK1 fusion	Cholangiocarcinoma Cholangiocarcinoma	larotrectinib Sensitive: C1 - Off-label	larotrectinib Sensitive: C1 - Off-label
BRAF V600 BRAF V600	Cholangiocarcinoma Cholangiocarcinoma	BRAF V600 BRAF V600	Cholangiocarcinoma Cholangiocarcinoma	vemurafenib Sensitive: C1 - Off-label	vemurafenib Sensitive: C1 - Off-label
MSI-H/dMMR MSI-H/dMMR	Cholangiocarcinoma Cholangiocarcinoma	MSI-H/dMMR MSI-H/dMMR	Cholangiocarcinoma Cholangiocarcinoma	pembrolizumab Sensitive: C1 - Off-label	pembrolizumab Sensitive: C1 - Off-label
BRAF V600E BRAF V600E	Cholangiocarcinoma Cholangiocarcinoma	BRAF V600E BRAF V600E	Cholangiocarcinoma Cholangiocarcinoma	trametinib + dabrafenib Sensitive: C1 - Off-label	trametinib + dabrafenib Sensitive: C1 - Off-label
NTRK2 fusion NTRK2 fusion	Cholangiocarcinoma Cholangiocarcinoma	NTRK2 fusion NTRK2 fusion	Cholangiocarcinoma Cholangiocarcinoma	entrectinib Sensitive: C1 - Off-label	entrectinib Sensitive: C1 - Off-label
NTRK3 fusion NTRK3 fusion	Cholangiocarcinoma Cholangiocarcinoma	NTRK3 fusion NTRK3 fusion	Cholangiocarcinoma Cholangiocarcinoma	entrectinib Sensitive: C1 - Off-label	entrectinib Sensitive: C1 - Off-label
NTRK1 fusion NTRK1 fusion	Cholangiocarcinoma Cholangiocarcinoma	NTRK1 fusion NTRK1 fusion	Cholangiocarcinoma Cholangiocarcinoma	entrectinib Sensitive: C1 - Off-label	entrectinib Sensitive: C1 - Off-label
FGFR2 translocation FGFR2 translocation	Cholangiocarcinoma Cholangiocarcinoma	FGFR2 translocation FGFR2 translocation	Cholangiocarcinoma Cholangiocarcinoma	pemigatinib Sensitive: C2 – Inclusion Criteria	pemigatinib Sensitive: C2 – Inclusion Criteria
FGFR2 fusion FGFR2 fusion	Cholangiocarcinoma Cholangiocarcinoma	FGFR2 fusion FGFR2 fusion	Cholangiocarcinoma Cholangiocarcinoma	ARQ 087 Sensitive: C2 – Inclusion Criteria	ARQ 087 Sensitive: C2 – Inclusion Criteria
FGFR2 mutation FGFR2 mutation	Cholangiocarcinoma Cholangiocarcinoma	FGFR2 mutation FGFR2 mutation	Cholangiocarcinoma Cholangiocarcinoma	infigratinib Sensitive: C2 – Inclusion Criteria	infigratinib Sensitive: C2 – Inclusion Criteria
FGFR2 mutation FGFR2 mutation	Cholangiocarcinoma Cholangiocarcinoma	FGFR2 mutation FGFR2 mutation	Cholangiocarcinoma Cholangiocarcinoma	TAS 120 Sensitive: C2 – Inclusion Criteria	TAS 120 Sensitive: C2 – Inclusion Criteria
IDH2 mutation IDH2 mutation	Cholangiocarcinoma Cholangiocarcinoma	IDH2 mutation IDH2 mutation	Cholangiocarcinoma Cholangiocarcinoma	dasatinib Sensitive: C2 – Inclusion Criteria	dasatinib Sensitive: C2 – Inclusion Criteria
IDH1 R132C IDH1 R132C	Cholangiocarcinoma Cholangiocarcinoma	IDH1 R132C IDH1 R132C	Cholangiocarcinoma Cholangiocarcinoma	ivosidenib Sensitive: C2 – Inclusion Criteria	ivosidenib Sensitive: C2 – Inclusion Criteria
FGFR2 mutation FGFR2 mutation	Cholangiocarcinoma Cholangiocarcinoma	FGFR2 mutation FGFR2 mutation	Cholangiocarcinoma Cholangiocarcinoma	TT-00420 Sensitive: C2 – Inclusion Criteria	TT-00420 Sensitive: C2 – Inclusion Criteria
HER-2 amplification HER-2 amplification	Cholangiocarcinoma Cholangiocarcinoma	HER-2 amplification HER-2 amplification	Cholangiocarcinoma Cholangiocarcinoma	trastuzumab Sensitive: C3 – Early Trials	trastuzumab Sensitive: C3 – Early Trials
DDR DDR	Cholangiocarcinoma Cholangiocarcinoma	DDR DDR	Cholangiocarcinoma Cholangiocarcinoma	lenvatinib + toripalimab Sensitive: C3 – Early Trials	lenvatinib + toripalimab Sensitive: C3 – Early Trials
PD-L1 expression PD-L1 expression	Cholangiocarcinoma Cholangiocarcinoma	PD-L1 expression PD-L1 expression	Cholangiocarcinoma Cholangiocarcinoma	lenvatinib + toripalimab Sensitive: C3 – Early Trials	lenvatinib + toripalimab Sensitive: C3 – Early Trials
ARID1A mutation ARID1A mutation	Cholangiocarcinoma Cholangiocarcinoma	ARID1A mutation ARID1A mutation	Cholangiocarcinoma Cholangiocarcinoma	Immunotherapy Sensitive: C3 – Early Trials	Immunotherapy Sensitive: C3 – Early Trials
KRAS G12C KRAS G12C	Cholangiocarcinoma Cholangiocarcinoma	KRAS G12C KRAS G12C	Cholangiocarcinoma Cholangiocarcinoma	MRTX849 Sensitive: C3 – Early Trials	MRTX849 Sensitive: C3 – Early Trials
POLE mutation POLE mutation	Cholangiocarcinoma Cholangiocarcinoma	POLE mutation POLE mutation	Cholangiocarcinoma Cholangiocarcinoma	PD1 inhibitor + PD-L1 inhibitor Sensitive: C3 – Early Trials	PD1 inhibitor + PD-L1 inhibitor Sensitive: C3 – Early Trials
POLE mutation POLE mutation	Cholangiocarcinoma Cholangiocarcinoma	POLE mutation POLE mutation	Cholangiocarcinoma Cholangiocarcinoma	PD-L1 inhibitor Sensitive: C3 – Early Trials	PD-L1 inhibitor Sensitive: C3 – Early Trials
POLE mutation POLE mutation	Cholangiocarcinoma Cholangiocarcinoma	POLE mutation POLE mutation	Cholangiocarcinoma Cholangiocarcinoma	PD1 inhibitor Sensitive: C3 – Early Trials	PD1 inhibitor Sensitive: C3 – Early Trials
MET-H MET-H	Cholangiocarcinoma Cholangiocarcinoma	MET-H MET-H	Cholangiocarcinoma Cholangiocarcinoma	cabozantinib tablet Sensitive: C3 – Early Trials	cabozantinib tablet Sensitive: C3 – Early Trials
TIMP1-L TIMP1-L	Cholangiocarcinoma Cholangiocarcinoma	TIMP1-L TIMP1-L	Cholangiocarcinoma Cholangiocarcinoma	cabozantinib tablet Sensitive: C3 – Early Trials	cabozantinib tablet Sensitive: C3 – Early Trials
FGFR2-BICC1 fusion FGFR2-BICC1 fusion	Cholangiocarcinoma Cholangiocarcinoma	FGFR2-BICC1 fusion FGFR2-BICC1 fusion	Cholangiocarcinoma Cholangiocarcinoma	TAS 120 Sensitive: C3 – Early Trials	TAS 120 Sensitive: C3 – Early Trials
FGFR2-SORBS1 fusion FGFR2-SORBS1 fusion	Cholangiocarcinoma Cholangiocarcinoma	FGFR2-SORBS1 fusion FGFR2-SORBS1 fusion	Cholangiocarcinoma Cholangiocarcinoma	TAS 120 Resistant: C3 – Early Trials	TAS 120 Resistant: C3 – Early Trials
FGFR3 fusion FGFR3 fusion	Cholangiocarcinoma Cholangiocarcinoma	FGFR3 fusion FGFR3 fusion	Cholangiocarcinoma Cholangiocarcinoma	Debio 1347 Sensitive: C3 – Early Trials	Debio 1347 Sensitive: C3 – Early Trials
FGFR2 fusion FGFR2 fusion	Cholangiocarcinoma Cholangiocarcinoma	FGFR2 fusion FGFR2 fusion	Cholangiocarcinoma Cholangiocarcinoma	Debio 1347 Sensitive: C3 – Early Trials	Debio 1347 Sensitive: C3 – Early Trials
FGFR1 fusion FGFR1 fusion	Cholangiocarcinoma Cholangiocarcinoma	FGFR1 fusion FGFR1 fusion	Cholangiocarcinoma Cholangiocarcinoma	Debio 1347 Sensitive: C3 – Early Trials	Debio 1347 Sensitive: C3 – Early Trials
TP53 mutation + FGFR2 rearrangement TP53 mutation + FGFR2 rearrangement	Cholangiocarcinoma Cholangiocarcinoma	TP53 mutation + FGFR2 rearrangement TP53 mutation + FGFR2 rearrangement	Cholangiocarcinoma Cholangiocarcinoma	TAS 120 Sensitive: C3 – Early Trials	TAS 120 Sensitive: C3 – Early Trials
TP53 mutation + FGFR2 fusion TP53 mutation + FGFR2 fusion	Cholangiocarcinoma Cholangiocarcinoma	TP53 mutation + FGFR2 fusion TP53 mutation + FGFR2 fusion	Cholangiocarcinoma Cholangiocarcinoma	TAS 120 Sensitive: C3 – Early Trials	TAS 120 Sensitive: C3 – Early Trials
PBRM1 mutation + FGFR2 fusion PBRM1 mutation + FGFR2 fusion	Cholangiocarcinoma Cholangiocarcinoma	PBRM1 mutation + FGFR2 fusion PBRM1 mutation + FGFR2 fusion	Cholangiocarcinoma Cholangiocarcinoma	TAS 120 Sensitive: C3 – Early Trials	TAS 120 Sensitive: C3 – Early Trials
PIK3CA mutation + FGFR2 rearrangement PIK3CA mutation + FGFR2 rearrangement	Cholangiocarcinoma Cholangiocarcinoma	PIK3CA mutation + FGFR2 rearrangement PIK3CA mutation + FGFR2 rearrangement	Cholangiocarcinoma Cholangiocarcinoma	TAS 120 Sensitive: C3 – Early Trials	TAS 120 Sensitive: C3 – Early Trials
PIK3CB mutation + FGFR2 rearrangement PIK3CB mutation + FGFR2 rearrangement	Cholangiocarcinoma Cholangiocarcinoma	PIK3CB mutation + FGFR2 rearrangement PIK3CB mutation + FGFR2 rearrangement	Cholangiocarcinoma Cholangiocarcinoma	TAS 120 Sensitive: C3 – Early Trials	TAS 120 Sensitive: C3 – Early Trials
PIK3R1 mutation + FGFR2 rearrangement PIK3R1 mutation + FGFR2 rearrangement	Cholangiocarcinoma Cholangiocarcinoma	PIK3R1 mutation + FGFR2 rearrangement PIK3R1 mutation + FGFR2 rearrangement	Cholangiocarcinoma Cholangiocarcinoma	TAS 120 Sensitive: C3 – Early Trials	TAS 120 Sensitive: C3 – Early Trials
BAP1 mutation + FGFR2 rearrangement BAP1 mutation + FGFR2 rearrangement	Cholangiocarcinoma Cholangiocarcinoma	BAP1 mutation + FGFR2 rearrangement BAP1 mutation + FGFR2 rearrangement	Cholangiocarcinoma Cholangiocarcinoma	TAS 120 Sensitive: C3 – Early Trials	TAS 120 Sensitive: C3 – Early Trials
BAP1 mutation + FGFR2 fusion BAP1 mutation + FGFR2 fusion	Cholangiocarcinoma Cholangiocarcinoma	BAP1 mutation + FGFR2 fusion BAP1 mutation + FGFR2 fusion	Cholangiocarcinoma Cholangiocarcinoma	TAS 120 Sensitive: C3 – Early Trials	TAS 120 Sensitive: C3 – Early Trials
IDH1 mutation + FGFR2 fusion IDH1 mutation + FGFR2 fusion	Cholangiocarcinoma Cholangiocarcinoma	IDH1 mutation + FGFR2 fusion IDH1 mutation + FGFR2 fusion	Cholangiocarcinoma Cholangiocarcinoma	TAS 120 Sensitive: C3 – Early Trials	TAS 120 Sensitive: C3 – Early Trials
IDH1 mutation + FGFR2 rearrangement IDH1 mutation + FGFR2 rearrangement	Cholangiocarcinoma Cholangiocarcinoma	IDH1 mutation + FGFR2 rearrangement IDH1 mutation + FGFR2 rearrangement	Cholangiocarcinoma Cholangiocarcinoma	TAS 120 Sensitive: C3 – Early Trials	TAS 120 Sensitive: C3 – Early Trials
FGFR2-BICC1 fusion FGFR2-BICC1 fusion	Cholangiocarcinoma Cholangiocarcinoma	FGFR2-BICC1 fusion FGFR2-BICC1 fusion	Cholangiocarcinoma Cholangiocarcinoma	infigratinib + PD 0173074 Sensitive: C3 – Early Trials	infigratinib + PD 0173074 Sensitive: C3 – Early Trials
FGFR2-AHCYL1 fusion FGFR2-AHCYL1 fusion	Cholangiocarcinoma Cholangiocarcinoma	FGFR2-AHCYL1 fusion FGFR2-AHCYL1 fusion	Cholangiocarcinoma Cholangiocarcinoma	infigratinib + PD 0173074 Sensitive: C3 – Early Trials	infigratinib + PD 0173074 Sensitive: C3 – Early Trials
FGFR2 Y376C FGFR2 Y376C	Cholangiocarcinoma Cholangiocarcinoma	FGFR2 Y376C FGFR2 Y376C	Cholangiocarcinoma Cholangiocarcinoma	ABSK091 Sensitive: C3 – Early Trials	ABSK091 Sensitive: C3 – Early Trials
BAP1 mutation BAP1 mutation	Cholangiocarcinoma Cholangiocarcinoma	BAP1 mutation BAP1 mutation	Cholangiocarcinoma Cholangiocarcinoma	cisplatin + gemcitabine Resistant: C3 – Early Trials	cisplatin + gemcitabine Resistant: C3 – Early Trials
MALT1 expression MALT1 expression	Cholangiocarcinoma Cholangiocarcinoma	MALT1 expression MALT1 expression	Cholangiocarcinoma Cholangiocarcinoma	regorafenib Sensitive: C3 – Early Trials	regorafenib Sensitive: C3 – Early Trials
EFNB2 positive EFNB2 positive	Cholangiocarcinoma Cholangiocarcinoma	EFNB2 positive EFNB2 positive	Cholangiocarcinoma Cholangiocarcinoma	sEphB4-HSA Sensitive: C3 – Early Trials	sEphB4-HSA Sensitive: C3 – Early Trials
EFNB2 negative EFNB2 negative	Cholangiocarcinoma Cholangiocarcinoma	EFNB2 negative EFNB2 negative	Cholangiocarcinoma Cholangiocarcinoma	sEphB4-HSA Sensitive: C3 – Early Trials	sEphB4-HSA Sensitive: C3 – Early Trials
HER-2 amplification HER-2 amplification	Cholangiocarcinoma Cholangiocarcinoma	HER-2 amplification HER-2 amplification	Cholangiocarcinoma Cholangiocarcinoma	ado-trastuzumab emtansine Sensitive: C3 – Early Trials	ado-trastuzumab emtansine Sensitive: C3 – Early Trials
FGFR2 mutation FGFR2 mutation	Cholangiocarcinoma Cholangiocarcinoma	FGFR2 mutation FGFR2 mutation	Cholangiocarcinoma Cholangiocarcinoma	pemigatinib Sensitive: C3 – Early Trials	pemigatinib Sensitive: C3 – Early Trials
FGFR2 C382R FGFR2 C382R	Cholangiocarcinoma Cholangiocarcinoma	FGFR2 C382R FGFR2 C382R	Cholangiocarcinoma Cholangiocarcinoma	pemigatinib Sensitive: C3 – Early Trials	pemigatinib Sensitive: C3 – Early Trials
DCK positive DCK positive	Cholangiocarcinoma Cholangiocarcinoma	DCK positive DCK positive	Cholangiocarcinoma Cholangiocarcinoma	gemcitabine Sensitive: C3 – Early Trials	gemcitabine Sensitive: C3 – Early Trials
FGFR2-KIAA1217 fusion FGFR2-KIAA1217 fusion	Cholangiocarcinoma Cholangiocarcinoma	FGFR2-KIAA1217 fusion FGFR2-KIAA1217 fusion	Cholangiocarcinoma Cholangiocarcinoma	ARQ 087 Sensitive: C3 – Early Trials	ARQ 087 Sensitive: C3 – Early Trials
FGFR2-KIAA1217 fusion FGFR2-KIAA1217 fusion	Cholangiocarcinoma Cholangiocarcinoma	FGFR2-KIAA1217 fusion FGFR2-KIAA1217 fusion	Cholangiocarcinoma Cholangiocarcinoma	Debio 1347 Sensitive: C3 – Early Trials	Debio 1347 Sensitive: C3 – Early Trials
FGFR2 mutation FGFR2 mutation	Cholangiocarcinoma Cholangiocarcinoma	FGFR2 mutation FGFR2 mutation	Cholangiocarcinoma Cholangiocarcinoma	FGFR2 inhibitor Resistant: C3 – Early Trials	FGFR2 inhibitor Resistant: C3 – Early Trials
LMNA-NTRK1 fusion + NTRK1 G595R LMNA-NTRK1 fusion + NTRK1 G595R	Cholangiocarcinoma Cholangiocarcinoma	LMNA-NTRK1 fusion + NTRK1 G595R LMNA-NTRK1 fusion + NTRK1 G595R	Cholangiocarcinoma Cholangiocarcinoma	TPX-0005 Sensitive: C3 – Early Trials	TPX-0005 Sensitive: C3 – Early Trials
dMMR/MSI-H + TMB-L dMMR/MSI-H + TMB-L	Cholangiocarcinoma Cholangiocarcinoma	dMMR/MSI-H + TMB-L dMMR/MSI-H + TMB-L	Cholangiocarcinoma Cholangiocarcinoma	PD1 inhibitor Resistant: C3 – Early Trials	PD1 inhibitor Resistant: C3 – Early Trials
PTEN mutation + MSI-H/dMMR PTEN mutation + MSI-H/dMMR	Cholangiocarcinoma Cholangiocarcinoma	PTEN mutation + MSI-H/dMMR PTEN mutation + MSI-H/dMMR	Cholangiocarcinoma Cholangiocarcinoma	PD1 inhibitor Resistant: C3 – Early Trials	PD1 inhibitor Resistant: C3 – Early Trials
FGFR2 F276C FGFR2 F276C	Cholangiocarcinoma Cholangiocarcinoma	FGFR2 F276C FGFR2 F276C	Cholangiocarcinoma Cholangiocarcinoma	pemigatinib Sensitive: C3 – Early Trials	pemigatinib Sensitive: C3 – Early Trials
FGFR2 translocation FGFR2 translocation	Cholangiocarcinoma Cholangiocarcinoma	FGFR2 translocation FGFR2 translocation	Cholangiocarcinoma Cholangiocarcinoma	ICP-192 Sensitive: C3 – Early Trials	ICP-192 Sensitive: C3 – Early Trials
FGFR2 fusion FGFR2 fusion	Cholangiocarcinoma Cholangiocarcinoma	FGFR2 fusion FGFR2 fusion	Cholangiocarcinoma Cholangiocarcinoma	ICP-192 Sensitive: C3 – Early Trials	ICP-192 Sensitive: C3 – Early Trials
IDH1 mutation IDH1 mutation	Cholangiocarcinoma Cholangiocarcinoma	IDH1 mutation IDH1 mutation	Cholangiocarcinoma Cholangiocarcinoma	metformin Sensitive: C3 – Early Trials	metformin Sensitive: C3 – Early Trials
FGFR2 mutation FGFR2 mutation	Cholangiocarcinoma Cholangiocarcinoma	FGFR2 mutation FGFR2 mutation	Cholangiocarcinoma Cholangiocarcinoma	Debio 1347 Sensitive: C3 – Early Trials	Debio 1347 Sensitive: C3 – Early Trials
HER-2 mutation HER-2 mutation	Cholangiocarcinoma Cholangiocarcinoma	HER-2 mutation HER-2 mutation	Cholangiocarcinoma Cholangiocarcinoma	trastuzumab Resistant: C4 – Case Studies	trastuzumab Resistant: C4 – Case Studies
FGFR2-NRAP fusion FGFR2-NRAP fusion	Cholangiocarcinoma Cholangiocarcinoma	FGFR2-NRAP fusion FGFR2-NRAP fusion	Cholangiocarcinoma Cholangiocarcinoma	TAS 120 Resistant: C4 – Case Studies	TAS 120 Resistant: C4 – Case Studies
MSI-H/dMMR + PD-1 expression + CD8 positive MSI-H/dMMR + PD-1 expression + CD8 positive	Cholangiocarcinoma Cholangiocarcinoma	MSI-H/dMMR + PD-1 expression + CD8 positive MSI-H/dMMR + PD-1 expression + CD8 positive	Cholangiocarcinoma Cholangiocarcinoma	pembrolizumab Sensitive: C4 – Case Studies	pembrolizumab Sensitive: C4 – Case Studies
FGFR2-CLIP1 fusion FGFR2-CLIP1 fusion	Cholangiocarcinoma Cholangiocarcinoma	FGFR2-CLIP1 fusion FGFR2-CLIP1 fusion	Cholangiocarcinoma Cholangiocarcinoma	pemigatinib Resistant: C4 – Case Studies	pemigatinib Resistant: C4 – Case Studies
FGFR2-OPTN fusion FGFR2-OPTN fusion	Cholangiocarcinoma Cholangiocarcinoma	FGFR2-OPTN fusion FGFR2-OPTN fusion	Cholangiocarcinoma Cholangiocarcinoma	infigratinib Resistant: C4 – Case Studies	infigratinib Resistant: C4 – Case Studies
FGFR2-BICC1 fusion FGFR2-BICC1 fusion	Cholangiocarcinoma Cholangiocarcinoma	FGFR2-BICC1 fusion FGFR2-BICC1 fusion	Cholangiocarcinoma Cholangiocarcinoma	infigratinib Resistant: C4 – Case Studies	infigratinib Resistant: C4 – Case Studies
VHL mutation VHL mutation	Cholangiocarcinoma Cholangiocarcinoma	VHL mutation VHL mutation	Cholangiocarcinoma Cholangiocarcinoma	sunitinib Sensitive: C4 – Case Studies	sunitinib Sensitive: C4 – Case Studies
PD-L1 overexpression PD-L1 overexpression	Cholangiocarcinoma Cholangiocarcinoma	PD-L1 overexpression PD-L1 overexpression	Cholangiocarcinoma Cholangiocarcinoma	pembrolizumab Sensitive: C4 – Case Studies	pembrolizumab Sensitive: C4 – Case Studies
EHBP1‐MET fusion EHBP1‐MET fusion	Cholangiocarcinoma Cholangiocarcinoma	EHBP1‐MET fusion EHBP1‐MET fusion	Cholangiocarcinoma Cholangiocarcinoma	crizotinib Sensitive: C4 – Case Studies	crizotinib Sensitive: C4 – Case Studies
MSI-H/dMMR + PD-L1 expression MSI-H/dMMR + PD-L1 expression	Cholangiocarcinoma Cholangiocarcinoma	MSI-H/dMMR + PD-L1 expression MSI-H/dMMR + PD-L1 expression	Cholangiocarcinoma Cholangiocarcinoma	pembrolizumab Sensitive: C4 – Case Studies	pembrolizumab Sensitive: C4 – Case Studies
BRCA1 mutation + PD-L1 expression BRCA1 mutation + PD-L1 expression	Cholangiocarcinoma Cholangiocarcinoma	BRCA1 mutation + PD-L1 expression BRCA1 mutation + PD-L1 expression	Cholangiocarcinoma Cholangiocarcinoma	pembrolizumab + olaparib Sensitive: C4 – Case Studies	pembrolizumab + olaparib Sensitive: C4 – Case Studies
BRAF mutation BRAF mutation	Cholangiocarcinoma Cholangiocarcinoma	BRAF mutation BRAF mutation	Cholangiocarcinoma Cholangiocarcinoma	LTT462 Sensitive: C4 – Case Studies	LTT462 Sensitive: C4 – Case Studies
HER-2 amplification HER-2 amplification	Cholangiocarcinoma Cholangiocarcinoma	HER-2 amplification HER-2 amplification	Cholangiocarcinoma Cholangiocarcinoma	pertuzumab/trastuzumab/hyaluronidase-zzxf Sensitive: C4 – Case Studies	pertuzumab/trastuzumab/hyaluronidase-zzxf Sensitive: C4 – Case Studies
FGFR2-TACC3 fusion FGFR2-TACC3 fusion	Cholangiocarcinoma Cholangiocarcinoma	FGFR2-TACC3 fusion FGFR2-TACC3 fusion	Cholangiocarcinoma Cholangiocarcinoma	ponatinib Sensitive: C4 – Case Studies	ponatinib Sensitive: C4 – Case Studies
FGFR2-TACC3 fusion FGFR2-TACC3 fusion	Cholangiocarcinoma Cholangiocarcinoma	FGFR2-TACC3 fusion FGFR2-TACC3 fusion	Cholangiocarcinoma Cholangiocarcinoma	pazopanib Sensitive: C4 – Case Studies	pazopanib Sensitive: C4 – Case Studies
FGFR2-OGA fusion FGFR2-OGA fusion	Cholangiocarcinoma Cholangiocarcinoma	FGFR2-OGA fusion FGFR2-OGA fusion	Cholangiocarcinoma Cholangiocarcinoma	ponatinib Sensitive: C4 – Case Studies	ponatinib Sensitive: C4 – Case Studies

Cholangiocarcinoma

Associations(148)

Associations
(148)